Diagnosing and management of iatrogenic moderate and severe ovarian hyperstymulation syndrome (OHSS) in clinical material

Folia Histochemica et Cytobiologica

Volumn 45, Issue SUPPL. 1, 2007, Pages 105-108

  Jakimiuk, Artur J ^a,b   Fritz, Anna ^a   Grzybowski, Wojciech ^a   Walecka, Irena ^a   Lewandowski, Piotr ^c  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

^c Infertility Center Novum   (Poland)

Author keywords

ART; Infertility; OHSS; Ovulation induction

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; DIURETIC AGENT;

ABDOMINAL BLEEDING; ADULT; ASCITES; BODY WEIGHT; CLINICAL ARTICLE; COLLOID; CONFERENCE PAPER; CRYSTALLOID; FEMALE; FLUID INTAKE; HUMAN; LABORATORY TEST; LAPAROTOMY; LUNG FUNCTION; OVARIECTOMY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOGENESIS; REHYDRATION;

EID: 44949124509     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstymulation syndrome. Best Pract Res Clin Obstet Gynecol. 2003;17(2):249-61.
2. Delbaere A, Smits G, Olatunbosun O et al. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod. 2004;19(3):486-9.
3. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obst Gynaecol. 2002;12:111-6.
4. Taher BM, Ghariabeh RA, Jarrah NS et al. Spontaneous ovarian hyperstimulation syndrome caused by hypothyroidism in adult. Eur J Obstet Gynecol Reprod Biol. 2004;112:107-9.
5. Barak V, Elchalal U, Edelstein M et al. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril. 2004;82(2):415-20.
6. Orvieto R. Controlled Ovarian Hyperstimulation - An Inflammatory State. J Soc Gynecol Investig. 2004;11(7):424-6.
7. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod. 2003;9(3):275-89.
8. Isik AZ, Vicdan K. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):208-12.
9. Golan A, Ron-El R, Soffer Y, Weinraub Z, Caspi E, Ovarian hyperstimulation syndrome: An update revive. Obstet Gynecol. 1989;44:430-40.
10. D'Angelo A, Amso N. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2002;(3):CD002811.
11. Delvigne A, Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int J Fertil Womens Med. 2002;47(5):211-26.
12. Enskog A, Henriksson M, Unander M et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999;71:808-14.
13. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74:429-38.
14. Goldsman MP, Pedram A, Dominguez CE et al. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63:268-72.
15. Levin ER, Rosen GF, Cassidenti DL et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 1998;102:1978-85.
16. McClure N, Healy DL, Rogers PA et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344:235-6.
17. Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril. 1999;71(3):562-563.
18. Pellicer A, Albert C, Mercader A et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482-489.
19. Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1999;71:645-651.
20. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2004;82,supl 1:81-86.
21. Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril. 2001;75(6):1228-1230.
22. Gokmen O, Ugur M, Ekin M et al. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization program: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 2001;96(2):187-192.
23. Koike T, Araki S, Minakami H et al. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstymulation syndrome. Hum Reprod. 2000;15(1):13-7.
24. Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril. 1989;51(5):791-795.